These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Sylvester RJ; Brausi MA; Kirkels WJ; Hoeltl W; Calais Da Silva F; Powell PH; Prescott S; Kirkali Z; van de Beek C; Gorlia T; de Reijke TM; Eur Urol; 2010 May; 57(5):766-73. PubMed ID: 20034729 [TBL] [Abstract][Full Text] [Related]
44. Case report: Mycobacterium bovis orchitis post intravesical Bacillus Calmette Guerin. Samannodi M; Villavicencio A; Zhao A; Chavez V; Ericsson CD IDCases; 2018; 14():e00465. PubMed ID: 30479960 [TBL] [Abstract][Full Text] [Related]
45. Can we treat bladder cancer with intravesical Bacillus Calmette-Guerin in patients with prior tuberculosis infection? A population-based cohort study. Hsu CW; Chiu YC; Hu HY; Fan YH; Hong SC; Cheng WM BMC Urol; 2020 Jul; 20(1):91. PubMed ID: 32641099 [TBL] [Abstract][Full Text] [Related]
48. [Multiorgan failure following intravesical bacillus Calmette-Guerin administration: a case report]. Baba Y; Ishizu K; Jojima K; Joko K; Nakamura K; Takihara H; Naito K Hinyokika Kiyo; 1992 Sep; 38(9):1063-5. PubMed ID: 1414761 [TBL] [Abstract][Full Text] [Related]
49. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. van der Meijden AP; Brausi M; Zambon V; Kirkels W; de Balincourt C; Sylvester R; J Urol; 2001 Aug; 166(2):476-81. PubMed ID: 11458050 [TBL] [Abstract][Full Text] [Related]
50. Bone marrow infection with bacillus Calmette-Guérin (BCG) after intravesical immunotherapy. Nemeth J; Stoiser B; Winkler HM; Müllauer L; Graninger W; Winkler S Wien Klin Wochenschr; 2008; 120(3-4):121-3. PubMed ID: 18322775 [TBL] [Abstract][Full Text] [Related]
51. Bladder contracture: review for intravesical bacillus Calmette-Guerin complication. Hameed A; Sezian N; Thwaini A Can J Urol; 2007 Dec; 14(6):3745-9. PubMed ID: 18163926 [TBL] [Abstract][Full Text] [Related]
52. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer. Shepherd AR; Shepherd E; Brook NR Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259 [TBL] [Abstract][Full Text] [Related]
53. BCG pyelonephritis following intravesical therapy for transitional cell carcinoma. Garcia JE; Thiel DD; Broderick GA Can J Urol; 2007 Apr; 14(2):3523-5. PubMed ID: 17466161 [TBL] [Abstract][Full Text] [Related]
54. Peritoneal tuberculosis presenting as recurrent peritonitis secondary to treatment with intravesical Bacillus Calmette-Guérin in a patient receiving peritoneal dialysis. Iqbal J; Raja M; Leung J Clin Kidney J; 2015 Feb; 8(1):107-8. PubMed ID: 25713719 [TBL] [Abstract][Full Text] [Related]
55. A Rare Case of Granulomatous Pneumonitis Due to Intravesical BCG for Bladder Cancer. Clérigo V; Castro A; Mourato T; Gomes C Acta Med Port; 2019 Apr; 32(4):316-320. PubMed ID: 31067427 [TBL] [Abstract][Full Text] [Related]
56. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG). Pansadoro V; Emiliozzi P; depaula F; Scarpone P; Pizzo M; Federico G; Martini M; Pansadoro A; Sternberg CN J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):223-7. PubMed ID: 16767936 [TBL] [Abstract][Full Text] [Related]